Equities

Genflow Biosciences PLC

GENF:LSE

Genflow Biosciences PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.15
  • Today's Change0.00 / 0.00%
  • Shares traded37.60k
  • 1 Year change23.92%
  • Beta--
Data delayed at least 20 minutes, as of Sep 27 2024 15:21 BST.
More ▼

Profile data is unavailable for this security.

About the company

Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.63m
  • Incorporated2021
  • Employees5.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
ValiRx Plc9.60k-2.04m2.62m8.002.62m8.00
TheraCryf PLC396.00k-3.14m2.93m9.002.93m9.00
Fusion Antibodies PLC1.14m-2.23m3.36m31.003.36m31.00
IXICO PLC6.00m-1.87m4.49m89.004.49m89.00
ImmuPharma PLC-69.96k-2.46m6.28m5.006.28m5.00
Genflow Biosciences PLC0.00-1.63m7.44m5.007.44m5.00
Synairgen plc0.00-6.92m7.67m36.007.67m36.00
Cizzle Biotechnology Holdings PLC0.00-1.72m7.75m67.007.75m67.00
LungLife AI Inc21.69k-3.34m8.50m15.008.50m15.00
Oxford Biodynamics PLC617.00k-11.11m11.91m45.0011.91m45.00
OptiBiotix Health PLC644.00k-2.04m16.53m5.0016.53m5.00
Hemogenyx Pharmaceuticals PLC0.00-6.69m20.67m17.0020.67m17.00
Data as of Sep 27 2024. Currency figures normalised to Genflow Biosciences PLC's reporting currency: UK Pound GBX

Institutional shareholders

9.15%Per cent of shares held by top holders
HolderShares% Held
Premier Fund Managers Ltd.as of 09 Apr 202432.00m9.15%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.